{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Togaviridae+Infections", "query": { "condition": "Togaviridae Infections" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Togaviridae+Infections&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T14:19:29.261Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00422292", "title": "Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meningococcal Meningitis", "Measles", "Mumps", "Rubella", "Varicella" ], "interventions": [ { "name": "Meningococcal Polysaccharide Diphtheria Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Measles, Mumps, Rubella and Varicella", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Months", "maximum_age": "12 Months", "sex": "ALL", "summary": "9 Months to 12 Months" }, "enrollment_count": 1664, "start_date": "2006-12", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-04-14", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 87, "location_summary": "Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Atascadero", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00422292" }, { "nct_id": "NCT05349617", "title": "Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chikungunya Virus" ], "interventions": [ { "name": "CHIKV VLP/adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 413, "start_date": "2022-05-12", "completion_date": "2023-08-08", "has_results": true, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 10, "location_summary": "Miami, Florida • Miami Lakes, Florida • St. Petersburg, Florida + 7 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05349617" }, { "nct_id": "NCT07520279", "title": "Xpert® Tropical Fever Test on GeneXpert® Edge X System", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malaria Fever", "Zika", "Dengue Fever", "Leptospirosis", "Chikungunya Virus Infection" ], "interventions": [ { "name": "Xpert Tropical Fever test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Cepheid", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 2500, "start_date": "2025-08-18", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07520279" }, { "nct_id": "NCT00384397", "title": "A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meningococcal Meningitis", "Measles", "Mumps", "Rubella", "Varicella" ], "interventions": [ { "name": "Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Meningococcal Polysaccharide Diphtheria Toxoid Conjugate", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "249 Days", "maximum_age": "305 Days", "sex": "ALL", "summary": "249 Days to 305 Days" }, "enrollment_count": 1128, "start_date": "2006-09", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2016-04-14", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 39, "location_summary": "Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384397" }, { "nct_id": "NCT05072080", "title": "A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chikungunya Virus" ], "interventions": [ { "name": "CHIKV VLP/adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "12 Years to 64 Years" }, "enrollment_count": 3258, "start_date": "2021-09-29", "completion_date": "2023-04-03", "has_results": true, "last_update_posted_date": "2024-08-30", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 47, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Banning", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05072080" }, { "nct_id": "NCT04131595", "title": "Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Equine Encephalitis" ], "interventions": [ { "name": "MVA-BN-WEV Dose 1", "type": "BIOLOGICAL" }, { "name": "MVA-BN-WEV Dose 2", "type": "BIOLOGICAL" }, { "name": "MVA-BN-WEV Dose 3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 45, "start_date": "2019-10-07", "completion_date": "2020-07-22", "has_results": false, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04131595" }, { "nct_id": "NCT00138255", "title": "Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Measles", "Mumps", "Rubella", "Varicella" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "16 Months", "sex": "ALL", "summary": "Up to 16 Months" }, "enrollment_count": 32, "start_date": "2004-06", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2010-08-27", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00138255" }, { "nct_id": "NCT01369394", "title": "Making Decisions About the Measles-Mumps-Rubella Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Measles", "Mumps", "Rubella", "MMR Vaccination" ], "interventions": [ { "name": "Behavioral: Computer-based tailoring system", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2011-06", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2014-12-10", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369394" }, { "nct_id": "NCT03776994", "title": "Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Encephalitis", "Encephalitis, Viral", "Infectious Encephalitis", "Virus Diseases", "Encephalomyelitis, Venezuelan Equine", "Brain Diseases", "Central Nervous System Diseases", "Central Nervous System Viral Diseases", "Alphavirus Infections", "Togaviridae Infections", "RNA Virus Infections", "Central Nervous System Infections", "Encephalomyelitis", "Physiological Effects of Drugs", "Vaccines", "Encephalomyelitis, Equine", "Nervous System Diseases" ], "interventions": [ { "name": "Vaccinations on Day 0, Day 28, and Day 140", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "SRI International", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 48, "start_date": "2018-07-17", "completion_date": "2021-04", "has_results": false, "last_update_posted_date": "2021-02-23", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 1, "location_summary": "Plymouth, Michigan", "locations": [ { "city": "Plymouth", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03776994" }, { "nct_id": "NCT01702428", "title": "Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rubella", "Measles", "Mumps" ], "interventions": [ { "name": "Priorix", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" }, { "name": "Havrix", "type": "BIOLOGICAL" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 5016, "start_date": "2012-11-09", "completion_date": "2015-04-16", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-07-23T14:19:29.261Z", "location_count": 62, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Daly City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01702428" } ] }